摘要
目的评价头孢哌酮钠舒巴坦钠治疗重症下呼吸道医院感染的临床疗效及安全性,并评价微生物学疗效。方法采用回顾性研究分析方法,分析2010年3月～2012年1月本院重症医学科,60例重症下呼吸道医院感染使用头孢哌酮钠舒巴坦钠治疗的资料。结果头孢哌酮钠舒巴坦钠总有效率达86.7%,细菌清除率为93.1%,未见明显不良反应。结论头孢哌酮钠舒巴坦钠是一种抗菌谱广、疗效显著、副作用少的抗菌药物,特别适用于重症下呼吸道医院感染的疾病治疗。
Objective To evaluate the clinical efficacy, safety and bactericidal action of cefoperazone sodium and sulbactam sodium on severe lower respiratory tract nosocomial infection. Methods In this retrospective study, the data of a total of 60 patients with severe nosocomial lower respiratory tract infections treated by cefoperazone sodium and sulbactam sodi- um from March 2010 to January 2012 were analyzed. Results The total efficacy rate of cefoperazone sodium and sulbactam sodium was 86.7%, the bacterial eradication rate was 93.1%, and no serious adverse reactions were found. Conclusion The study indicates cefoperazone sodium and sulbaetam sodium is a kind of valuable antimicrobial agent with wide antimicrobial spectrum, notable effect, few side effect, especially in patients with severe nosocomial lower respiratory tract infections.
出处
《中国当代医药》
2012年第23期117-118,共2页
China Modern Medicine
关键词
头孢哌酮钠舒巴坦钠
重症
下呼吸道感染
疗效
Cefoperazone sodium and sulbactam sodium
Severe
Lower respiratory tract infections
Clinical efficacy
